BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds

Reuters11-01

BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds

BioHarvest Sciences Inc. has announced a strategic CDMO (Contract Development and Manufacturing Organization) agreement with Saffron Tech Ltd., a company specializing in advanced saffron cultivation methods. The collaboration aims to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform, which allows for scalable and consistent production of plant-based molecules without traditional plant cultivation. Under the terms of the agreement, Saffron Tech will own 75% and BioHarvest 25% of the developed saffron compositions and associated intellectual property rights. Following development, BioHarvest plans to manufacture the compounds at scale and introduce a new line of saffron-based nutraceutical products targeting cognitive function, eye health, and antioxidant benefits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000013), on October 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580416698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-01 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580416698","market":"us","top_or_hot":-1,"title":"BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioHarvest Sciences Inc. has announced a strategic CDMO (Contract Development and Manufacturing Organization) agreement with Saffron Tech Ltd., a company specializing in advanced saffron cultivation methods. The collaboration aims to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform, which allows for scalable and consistent production of plant-based molecules without traditional plant cultivation. Under the terms of the agreement, Saffron Tech will own 75% and BioHarvest 25% of the developed saffron compositions and associated intellectual property rights. Following development, BioHarvest plans to manufacture the compounds at scale and introduce a new line of saffron-based nutraceutical products targeting cognitive function, eye health, and antioxidant benefits.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BHST\">Bioharvest Sciences</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000013), on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-01 04:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioHarvest Sciences Inc. has announced a strategic CDMO (Contract Development and Manufacturing Organization) agreement with Saffron Tech Ltd., a company specializing in advanced saffron cultivation methods. The collaboration aims to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform, which allows for scalable and consistent production of plant-based molecules without traditional plant cultivation. Under the terms of the agreement, Saffron Tech will own 75% and BioHarvest 25% of the developed saffron compositions and associated intellectual property rights. Following development, BioHarvest plans to manufacture the compounds at scale and introduce a new line of saffron-based nutraceutical products targeting cognitive function, eye health, and antioxidant benefits.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BHST\">Bioharvest Sciences</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000013), on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL5F6KXR:1","article_id":"2580416698","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580416698","pubTimestamp":1761942341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioHarvest Sciences Inc. has announced a strategic CDMO  agreement with Saffron Tech Ltd., a company specializing in advanced saffron cultivation methods. The collaboration aims to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform, which allows for scalable and consistent production of plant-based molecules without traditional plant cultivation. Under the terms of the agreement, Saffron Tech will own 75% and BioHarvest 25% of the developed saffron compositions and associated intellectual property rights. Following development, BioHarvest plans to manufacture the compounds at scale and introduce a new line of saffron-based nutraceutical products targeting cognitive function, eye health, and antioxidant benefits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BHST":"BIOHARVEST SCIENCES INC"},"translate_title":"BioHarvest Sciences和Saffron Tech合作开发藏红花衍生化合物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHST":0.9},"content_text":"BioHarvest Sciences and Saffron Tech Partner to Develop Saffron-Derived Compounds\n    \n\n        BioHarvest Sciences Inc. has announced a strategic CDMO (Contract Development and Manufacturing Organization) agreement with Saffron Tech Ltd., a company specializing in advanced saffron cultivation methods. The collaboration aims to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform, which allows for scalable and consistent production of plant-based molecules without traditional plant cultivation. Under the terms of the agreement, Saffron Tech will own 75% and BioHarvest 25% of the developed saffron compositions and associated intellectual property rights. Following development, BioHarvest plans to manufacture the compounds at scale and introduce a new line of saffron-based nutraceutical products targeting cognitive function, eye health, and antioxidant benefits.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000013), on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580416698","isCrawlerRequest":true}